Erytech Pharma has launched a Phase II study of Eryasp in pancreatic cancer. Erytech completed a Phase I study in late-stage pancreas cancer, confirming  tolerability, and will continue the development in solid tumors by performing a Phase II study in second line pancreas cancer. In a study of about 100 patients, Eryasp in addition to the best standard of care will be compared to the best standard of care alone in a 2:1 randomization. Thanks to an exclusive license from the National Institutes ...